Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review

doi:10.12998/wjcc.v14.i12.119171

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 12

This Article

(34)

(43)

(0)

(1426)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Cases. Apr 26, 2026; 14(12): 119171
Published online Apr 26, 2026. doi: 10.12998/wjcc.v14.i12.119171

Table 3 Grading of Recommendations Assessment, Development and Evaluation quality of evidence assessment for key comparisons

Comparison	Outcome	Initial quality	Risk of bias	Inconsistency	Indirectness	Imprecision	Publication bias	Final quality	Comments
Lebrikizumab vs dupilumab	IGA 0/1 at week 16	High	No serious	No serious	Serious (-1)	No serious	Undetected	Moderate	Indirect comparison via NMA
Lebrikizumab vs dupilumab	EASI 75 at week 16	High	No serious	No serious	Serious (-1)	No serious	Undetected	Moderate	Indirect comparison via NMA
Lebrikizumab vs tralokinumab	IGA 0/1 at week 16	High	No serious	No serious	No serious to serious	No serious	Undetected	Moderate to high	Consistent superiority
Lebrikizumab vs tralokinumab	EASI 75 at week 16	High	No serious	No serious	No serious to serious	No serious	Undetected	Moderate to high	Consistent superiority
Lebrikizumab vs baricitinib	IGA 0/1 at week 16	High	No serious	No serious	Serious (-1)	No serious	Undetected	Moderate	Indirect comparison via NMA
Lebrikizumab vs abrocitinib	IGA 0/1 at week 12/16	High	No serious	No serious	Serious (-1)	No serious	Undetected	Moderate	Different timepoints
Lebrikizumab vs upadacitinib 30 mg	IGA 0/1 at week 16	High	No serious	No serious	Serious (-1)	No serious	Undetected	Moderate	Clear inferiority

EASI: Eczema Area and Severity Index; IGA: Investigator global assessment; NMA: Network meta-analysis.

Full Size Table

Citation: Alphonse C, Irfan M, Céspedes SCT, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Mendoza LAG, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; 14(12): 119171
URL: https://www.wjgnet.com/2307-8960/full/v14/i12/119171.htm
DOI: https://dx.doi.org/10.12998/wjcc.v14.i12.119171

Alphonse C, Irfan M, Céspedes SCT, Nwanejuafor C, Nayeem K, Hertan E, Mohan V, Gupta H, Fatima NUA, Mendoza LAG, Sardar A, Diaz AM, Jawed I. Comparing lebrikizumab with other systemic immunomodulators for moderate to severe atopic dermatitis: An updated systematic review. World J Clin Cases 2026; 14(12): 119171 [DOI: 10.12998/wjcc.v14.i12.119171]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.